{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:10:07Z","timestamp":1785363007216,"version":"3.55.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T00:00:00Z","timestamp":1470268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004431","name":"Directorate-General for Research and Innovation","doi-asserted-by":"publisher","award":["280873 (ADITEC)"],"award-info":[{"award-number":["280873 (ADITEC)"]}],"id":[{"id":"10.13039\/100004431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004431","name":"Directorate-General for Research and Innovation","doi-asserted-by":"publisher","award":["261472 (STOPENTERICS)"],"award-info":[{"award-number":["261472 (STOPENTERICS)"]}],"id":[{"id":"10.13039\/100004431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"crossref","award":["115308 (BioVacSafe)"],"award-info":[{"award-number":["115308 (BioVacSafe)"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0157385","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T17:43:54Z","timestamp":1470332634000},"page":"e0157385","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review"],"prefix":"10.1371","volume":"11","author":[{"given":"Vincent","family":"Muturi-Kioi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Anemona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Loulergue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline L.","family":"Bodinham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Aerssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Groth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Saul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audino","family":"Podda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,4]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2214.2008.00864_6.x","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children","volume":"34","author":"R Reading","year":"2008","journal-title":"Child: Care, Health and Development"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1542\/peds.2011-1111","article-title":"The risk of immune thrombocytopenic purpura after vaccination in children and adolescents","volume":"129","author":"ST O'Leary","year":"2012","journal-title":"Pediatrics"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/lc.1999.v133.a94931","article-title":"Benign ethnic neutropenia: what is a normal absolute neutrophil count?","volume":"133","author":"TB Haddy","year":"1999","journal-title":"The Journal of laboratory and clinical medicine"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archinte.1991.00400030063011","article-title":"Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks","volume":"151","author":"WW Reed","year":"1991","journal-title":"Archives of internal medicine"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/jcp.49.8.664","article-title":"Ethnic and sex differences in the total and differential white cell count and platelet count","volume":"49","author":"BJ Bain","year":"1996","journal-title":"Journal of clinical pathology"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.4049\/jimmunol.181.8.5183","article-title":"Homeostatic regulation of blood neutrophil counts","volume":"181","author":"S von Vietinghoff","year":"2008","journal-title":"Journal of immunology (Baltimore, Md: 1950)"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"e1000360","DOI":"10.1371\/journal.pgen.1000360","article-title":"Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene","volume":"5","author":"D Reich","year":"2009","journal-title":"PLoS Genet"},{"issue":"1","key":"ref8","first-page":"23","article-title":"The outcome of bacterial infection in subjects with benign familial leukopenia (BFL)","volume":"39","author":"Y Shoenfeld","year":"1985","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"e0134478","DOI":"10.1371\/journal.pone.0134478","article-title":"Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB","volume":"10","author":"C Gerke","year":"2015","journal-title":"PloS one"},{"key":"ref10","unstructured":"Administration FUSFaD. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"e1267","DOI":"10.1371\/journal.pntd.0001267","article-title":"A single dose of the DENV-1 candidate vaccine rDEN1Delta30 is strongly immunogenic and induces resistance to a second dose in a randomized trial","volume":"5","author":"AP Durbin","year":"2011","journal-title":"PLoS neglected tropical diseases"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"D Morrison","year":"2010","journal-title":"The Journal of infectious diseases"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1086\/319215","article-title":"Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women","volume":"32","author":"CK Cunningham","year":"2001","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.292.6.709","article-title":"Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial","volume":"292","author":"KL Kotloff","year":"2004","journal-title":"Jama"},{"issue":"31","key":"ref15","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1016\/j.vaccine.2009.04.077","article-title":"A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1\/Alhydrogel with CPG 7909, using two different formulations and dosing intervals","volume":"27","author":"RD Ellis","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"e22271","DOI":"10.1371\/journal.pone.0022271","article-title":"Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1\/Alhydrogel+CPG 7909","volume":"6","author":"CJ Duncan","year":"2011","journal-title":"PloS one"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4161\/hv.19983","article-title":"A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults","volume":"8","author":"EA Sheldon","year":"2012","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/01.aids.0000237363.33994.45","article-title":"HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers","volume":"20","author":"EJ McFarland","year":"2006","journal-title":"AIDS (London, England)"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"e67177","DOI":"10.1371\/journal.pone.0067177","article-title":"Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects","volume":"8","author":"TN Dieye","year":"2013","journal-title":"PloS one"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4161\/hv.2.4.2944","article-title":"The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers","volume":"2","author":"AP Durbin","year":"2006","journal-title":"Human vaccines"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4269\/ajtmh.2003.69.48","article-title":"Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine","volume":"69","author":"R Edelman","year":"2003","journal-title":"The American journal of tropical medicine and hygiene"},{"issue":"22","key":"ref22","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.vaccine.2008.02.071","article-title":"Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa","volume":"26","author":"W Jaoko","year":"2008","journal-title":"Vaccine"},{"issue":"36","key":"ref23","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.vaccine.2009.05.099","article-title":"Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults","volume":"27","author":"RA Karron","year":"2009","journal-title":"Vaccine"},{"issue":"9","key":"ref24","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.vaccine.2005.09.029","article-title":"Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults","volume":"24","author":"S Kitchener","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4269\/ajtmh.2008.79.678","article-title":"Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity","volume":"79","author":"JH McArthur","year":"2008","journal-title":"The American journal of tropical medicine and hygiene"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"e78679","DOI":"10.1371\/journal.pone.0078679","article-title":"A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"A Ouedraogo","year":"2013","journal-title":"PloS one"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4161\/hv.5.1.6348","article-title":"Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults","volume":"5","author":"W Sun","year":"2009","journal-title":"Human vaccines"},{"issue":"28","key":"ref28","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1016\/j.vaccine.2009.03.082","article-title":"A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults","volume":"27","author":"KR Talaat","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"e55571","DOI":"10.1371\/journal.pone.0055571","article-title":"DNA prime\/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity","volume":"8","author":"I Chuang","year":"2013","journal-title":"PloS one"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"e24586","DOI":"10.1371\/journal.pone.0024586","article-title":"Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults","volume":"6","author":"M Sedegah","year":"2011","journal-title":"PloS one"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4269\/ajtmh.2011.10-0501","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants","volume":"85","author":"V Watanaveeradej","year":"2011","journal-title":"The American journal of tropical medicine and hygiene"},{"issue":"9959","key":"ref32","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial","volume":"384","author":"LJ Chang","year":"2014","journal-title":"Lancet"},{"issue":"44","key":"ref33","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1016\/j.vaccine.2014.08.034","article-title":"PedVacc 002: a phase I\/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi","volume":"32","author":"IN Njuguna","year":"2014","journal-title":"Vaccine"},{"issue":"48","key":"ref34","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers","volume":"31","author":"AP Durbin","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690024","article-title":"Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates","volume":"69","author":"W Sun","year":"2003","journal-title":"The American journal of tropical medicine and hygiene"},{"issue":"22","key":"ref36","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines","volume":"29","author":"RZ Capeding","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4161\/hv.2.6.3494","article-title":"rDEN2\/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults","volume":"2","author":"AP Durbin","year":"2006","journal-title":"Human vaccines"},{"issue":"8","key":"ref38","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1089\/aid.2009.0242","article-title":"A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus","volume":"26","author":"E Vardas","year":"2010","journal-title":"AIDS research and human retroviruses"},{"issue":"4\u20135","key":"ref39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0264-410X(00)00191-2","article-title":"Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus\u2014poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans","volume":"19","author":"N Kanesa-thasan","year":"2000","journal-title":"Vaccine"},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/INF.0b013e3181998f06","article-title":"A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella","volume":"28","author":"AA Gershon","year":"2009","journal-title":"The Pediatric infectious disease journal"},{"issue":"33","key":"ref41","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1016\/j.vaccine.2013.05.075","article-title":"Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles","volume":"31","author":"JC Lindow","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","article-title":"Phase I\/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents","volume":"29","author":"GK Siberry","year":"2010","journal-title":"The Pediatric infectious disease journal"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/INF.0b013e318236c67b","article-title":"Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children","volume":"31","author":"GK Siberry","year":"2012","journal-title":"The Pediatric infectious disease journal"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.vaccine.2007.12.015","article-title":"Evaluation of the Langat\/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers","volume":"26","author":"PF Wright","year":"2008","journal-title":"Vaccine"},{"issue":"23","key":"ref45","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1016\/j.vaccine.2006.03.066","article-title":"Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)","volume":"24","author":"V Sanchez","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"e4401","DOI":"10.1371\/journal.pone.0004401","article-title":"CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa","volume":"4","author":"E Karita","year":"2009","journal-title":"PloS one"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0157385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T23:48:07Z","timestamp":1656978487000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0157385"}},"subtitle":[],"editor":[{"given":"David Joseph","family":"Diemert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,4]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0157385","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,4]]}}}